201 related articles for article (PubMed ID: 29066476)
1. Role of CDKN2C Fluorescence In Situ Hybridization in the Management of Medullary Thyroid Carcinoma.
El Naofal M; Kim A; Yon HY; Baity M; Ming Z; Bui-Griffith J; Tang Z; Robinson M; Grubbs EG; Cote GJ; Hu P
Ann Clin Lab Sci; 2017 Sep; 47(5):523-528. PubMed ID: 29066476
[TBL] [Abstract][Full Text] [Related]
2. Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma.
Grubbs EG; Williams MD; Scheet P; Vattathil S; Perrier ND; Lee JE; Gagel RF; Hai T; Feng L; Cabanillas ME; Cote GJ
Thyroid; 2016 Nov; 26(11):1553-1562. PubMed ID: 27610696
[TBL] [Abstract][Full Text] [Related]
3. Novel use of a Clinical Laboratory Improvements Amendments (CLIA)-certified Cyclin-Dependent Kinase N2C (CDKN2C) loss assay in sporadic medullary thyroid carcinoma.
Maxwell JE; Gule-Monroe MK; Subbiah V; Hu M; Perrier ND; Cabanillas ME; Lee JE; Graham PH; Cote GJ; Busaidy NL; Grubbs EG
Surgery; 2020 Jan; 167(1):80-86. PubMed ID: 31648931
[TBL] [Abstract][Full Text] [Related]
4. Analytical Performance of a Gene Expression Classifier for Medullary Thyroid Carcinoma.
Pankratz DG; Hu Z; Kim SY; Monroe RJ; Wong MG; Traweek ST; Kloos RT; Walsh PS; Kennedy GC
Thyroid; 2016 Nov; 26(11):1573-1580. PubMed ID: 27605259
[TBL] [Abstract][Full Text] [Related]
5. Synergistic effect of oncogenic RET and loss of p18 on medullary thyroid carcinoma development.
van Veelen W; van Gasteren CJ; Acton DS; Franklin DS; Berger R; Lips CJ; Höppener JW
Cancer Res; 2008 Mar; 68(5):1329-37. PubMed ID: 18316595
[TBL] [Abstract][Full Text] [Related]
6. Mutations in CDKN2C (p18) and CDKN2D (p19) may cause sporadic parathyroid adenoma.
Gluick T; Yuan Z; Libutti SK; Marx SJ
Endocr Relat Cancer; 2013 Dec; 20(6):L27-9. PubMed ID: 24127162
[No Abstract] [Full Text] [Related]
7. Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer.
Ji JH; Oh YL; Hong M; Yun JW; Lee HW; Kim D; Ji Y; Kim DH; Park WY; Shin HT; Kim KM; Ahn MJ; Park K; Sun JM
PLoS Genet; 2015 Aug; 11(8):e1005467. PubMed ID: 26295973
[TBL] [Abstract][Full Text] [Related]
8. ATF4 Targets RET for Degradation and Is a Candidate Tumor Suppressor Gene in Medullary Thyroid Cancer.
Bagheri-Yarmand R; Williams MD; Grubbs EG; Gagel RF
J Clin Endocrinol Metab; 2017 Mar; 102(3):933-941. PubMed ID: 27935748
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of RET isoforms in normal thyroid tissues, papillary and medullary thyroid carcinomas.
Ramone T; Romei C; Ciampi R; Tacito A; Piaggi P; Torregrossa L; Ugolini C; Elisei R
Endocrine; 2019 Sep; 65(3):623-629. PubMed ID: 31278686
[TBL] [Abstract][Full Text] [Related]
10. Update on C-Cell Neuroendocrine Neoplasm: Prognostic and Predictive Histopathologic and Molecular Features of Medullary Thyroid Carcinoma.
Jung CK; Agarwal S; Hang JF; Lim DJ; Bychkov A; Mete O
Endocr Pathol; 2023 Mar; 34(1):1-22. PubMed ID: 36890425
[TBL] [Abstract][Full Text] [Related]
11. The prevalence of somatic RAS mutations in medullary thyroid cancer - a Polish population study.
Oczko-Wojciechowska M; Pfeifer A; Rusinek D; Pawlaczek A; Zebracka-Gala J; Kowalska M; Kowal M; Swierniak M; Krajewska J; Gawlik T; Chmielik E; Czarniecka A; Szpak-Ulczok S; Jarząb B
Endokrynol Pol; 2015; 66(2):121-5. PubMed ID: 25931041
[TBL] [Abstract][Full Text] [Related]
12. Molecular signatures of medullary thyroid carcinoma by matrix-assisted laser desorption/ionisation mass spectrometry imaging.
Smith A; Galli M; Piga I; Denti V; Stella M; Chinello C; Fusco N; Leni D; Manzoni M; Roversi G; Garancini M; Pincelli AI; Cimino V; Capitoli G; Magni F; Pagni F
J Proteomics; 2019 Jan; 191():114-123. PubMed ID: 29581064
[TBL] [Abstract][Full Text] [Related]
13. Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives.
Ceolin L; Duval MADS; Benini AF; Ferreira CV; Maia AL
Endocr Relat Cancer; 2019 Aug; 26(9):R499-R518. PubMed ID: 31252403
[TBL] [Abstract][Full Text] [Related]
14. Investigation of tumor suppressor genes apart from VHL on 3p by deletion mapping in sporadic clear cell renal cell carcinoma (cRCC).
Singh RB; Amare Kadam PS
Urol Oncol; 2013 Oct; 31(7):1333-42. PubMed ID: 21962529
[TBL] [Abstract][Full Text] [Related]
15. Diversity of mutations in the RET proto-oncogene and its oncogenic mechanism in medullary thyroid cancer.
Hedayati M; Zarif Yeganeh M; Sheikholeslami S; Afsari F
Crit Rev Clin Lab Sci; 2016 Aug; 53(4):217-27. PubMed ID: 26678667
[TBL] [Abstract][Full Text] [Related]
16. Frequent loss of the CDKN2C (p18INK4c) gene product in pituitary adenomas.
Kirsch M; Mörz M; Pinzer T; Schackert HK; Schackert G
Genes Chromosomes Cancer; 2009 Feb; 48(2):143-54. PubMed ID: 18973139
[TBL] [Abstract][Full Text] [Related]
17. Histopathology of C Cells and Medullary Thyroid Carcinoma.
Schmid KW
Recent Results Cancer Res; 2015; 204():41-60. PubMed ID: 26494383
[TBL] [Abstract][Full Text] [Related]
18. Modulatory Role of Single Nucleotide Polymorphisms of Distinct Genetic Pathways on Clinical Behavior of Medullary Thyroid Carcinoma.
Mishra V; Kowtal P; Rane P; Sarin R
Asian Pac J Cancer Prev; 2020 May; 21(5):1289-1293. PubMed ID: 32458635
[TBL] [Abstract][Full Text] [Related]
19. Medullary Thyroid Carcinoma: Recent Advances Including MicroRNA Expression.
Chu YH; Lloyd RV
Endocr Pathol; 2016 Dec; 27(4):312-324. PubMed ID: 27539727
[TBL] [Abstract][Full Text] [Related]
20. High resolution array-comparative genomic hybridization profiling reveals deoxyribonucleic acid copy number alterations associated with medullary thyroid carcinoma.
Ye L; Santarpia L; Cote GJ; El-Naggar AK; Gagel RF
J Clin Endocrinol Metab; 2008 Nov; 93(11):4367-72. PubMed ID: 18765511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
